Intercell AG (VSE: ICLL)

https://www.intercell.com

Intercell AG is an innovative biotechnology company that develops novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical needs. Intercell’s vaccine to prevent Japanese Encephalitis is the Company’s first product on the market. The Company’s technology platform includes an antigen-discovery system and human anti-infective monoclonal antibody discovery system, adjuvants and a novel patch-based delivery system (Vaccine Patch, Vaccine Enhancement Patch). Based on these technologies, Intercell has strategic partnerships, including with a number of pharmaceutical companies, with GSK, Novartis, Merck & Co., Inc., sanofi-aventis, and Romark. The Company’s pipeline of investigational products includes a Pseudomonas aeruginosa vaccine candidate (Phase II), a vaccine to prevent Pandemic Influenza combining our Vaccine Enhancement Patch with an injected vaccine (Phase I/II), a vaccine program for S. aureus, which is being developed with Merck & Co., Inc. (Phase II/III), a vaccine candidate for Pneumococcus (Phase I) as well as a combination treatment approach for Hepatitis C (Phase II). A vaccine candidate against infections with C. difficile has entered Phase I clinical trials in 2010. In addition, further products focused on infectious diseases are in pre-clinical development. Intercell is listed on the Vienna stock exchange under the symbol “ICLL” (U.S. level one ADR symbol “INRLY”). *

	Start	1998-01-01 established
	End	2013-05-28 renamed
	Group	Valneva (Group)
	Today	Valneva Austria GmbH
	Successor	Intercell Austria AG
	Industry	vaccine
	Person	Lingelbach, Thomas (Intercell 201106– CEO before COO before 2001– Chiron Behring)
	Person 2	Kandera, Reinhard (Hookipa Biotech 201704– CFO before Valneva CFO + Intercell CFO + Deutsche Bank AG)

	Region	Wien (Vienna)
	Country	Austria
	Street	3 Campus-Vienna-Biocenter
	City	1030 Wien
	Tel	+43-1-20620-0
		Address record changed: 2020-12-02

Basic data	Employees	D: 101 to 500 (2011-03-01)
	Currency	EUR
	Annual sales	35,665,000 (revenues (2012) 2012-12-31)
	Profit	-25,337,000 (2012-12-31)
	Cash	44,933,000 (2012-12-31)

		* Document for ï¿½About Sectionï¿½: Intercell AG. (3/1/11). "Press Release: Intercell Announces Q4 and Preliminary Full Year 2010 Financial Results. Growing Revenues from Ixiaro/Jespect Sales – Significant Net Loss Due to One-time Non-cash Effects". Vienna.

		Record changed: 2017-04-01